Premium
Variations of choroidal thickness in exsudative AMD before and after treatment
Author(s) -
MAUGETFAYSSE M,
COSCAS G
Publication year - 2013
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2013.3216.x
Subject(s) - ranibizumab , medicine , ophthalmology , macular degeneration , optical coherence tomography , foveal , surgery , retinal , bevacizumab , chemotherapy
PURPOSE: To evaluate choroidal morphological changes 3 and 6 months after intravitreal injection of Ranibizumab for exudative age related macular degeneration. METHODS: Retrospective, nonrandomized study, including patients with exudative AMD treated with Ranibizumab intravitreal injection and followed during 6 months. Non treated eye of AMD patients will be consider as control. All patients underwent a complete ophthalmological examination. At baseline, 3 months and 6 months, foveal and non‐subfoveal areas were evaluated with Spectralis optical coherence tomography on both eye: under the fovea and at 500 and 1500 μm nasally and temporaly . RESULTS and CONCLUSION: All studied eyes had exudative AMD at baseline treated with at least 3 Ranibizumab (Three Ranibizumab followed by injections if necessary were done for each patients). The results will be presented during the meeting.